Feb 3, 2017 · 21m · mad
Drug Discovery as a Data Problem // Sajith Wickramasekara, Benchling (FirstMark's Data Driven)
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Sajith Wickramasekara, founder and CEO of Benchling, presents how modern cloud software and standard software engineering principles transform life science research and antibody discovery into structured, solvable data problems.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Matt holds 5.2% of the talking time here. How this is scored →
Matt as informed peer 0.7 Guest teaching 3.0 Guest disagreement 0.4 Matt pushing back 0.1
speaking balance: gold is Matt, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 13:50 Mild pushback on industry readiness
Sajith gently checks the host's premise about rapid adoption by clarifying 'yes and no' and explaining that life sciences inherently lag technology by one or two cycles.
Hardest push from Matt ▶ 14:20 Probing early adopter demographicMatt Turck follows up on Sajith's answer by asking whether adoption is driven by younger demographics or smaller biotechs specifically.
Biggest teaching moment ▶ 15:25 Deconstructing cloud security theater and shadow ITSajith educates the audience on security reality versus security theater, showing how researchers secretly use personal Gmails when legacy corporate tools fail them.
Matt holds his own ▶ 17:10 Connecting cloud data adoption trends across industriesMatt Turck synthesizes the guest's response with a broader macro observation about how enterprise data is rapidly shifting to the cloud across all showcase events.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Matt as informed peer | Guest teaching | Guest disagreement | Matt pushing back | Why |
|---|---|---|---|---|---|---|
| The Software Collaboration Gap in Life Sciences | 0 | 3 | 0 | 0 | In this opening monologue segment, Sajith explains the contrast between modern software engineering collaboration and the paper, email, and Excel workflows prevalent in life sciences. Because this is a monologue presentation, host expertise and pushback are scored zero. | |
| Benchling's Integrated R&D Platform Solution | 0 | 3 | 0 | 0 | Sajith details how biotechs attempt complex antibody discovery using fragmented tools like Word, Excel, and FileMaker Pro. This monologue contains no host participation, so host scores remain zero. | |
| Step 2: Biological Registration and Structured Data Tracking | 0 | 3 | 0 | 0 | Sajith describes Benchling's biological registration system and structured database built on top of Postgres. As a monologue segment, host engagement scores are zero. | |
| Step 3: Study Management and Process Automation | 0 | 2 | 0 | 0 | Sajith explains how study management and process automation standardizes experimental workflows in research labs. This continues the monologue presentation format with no host interaction. | |
| Presentation Conclusion and Key Takeaways | 2 | 3 | 1 | 1 | Sajith wraps up his talk and host Matt Turck kicks off Q&A with polite questions regarding market readiness and early adopter profiles. The interaction is conversational and gentle, with low host pushback and mild guest schooling regarding tech lag in life sciences. | |
| Q&A: Cloud Security Concerns and Analytics Integration | 2 | 4 | 1 | 0 | Audience members ask about cloud security paranoia and analytics capabilities, which Sajith answers by describing shadow IT and ETL integrations. Host Matt Turck chimes in briefly to validate the trend of data moving to the cloud. | |
| Q&A: Software Boundaries and Notification Systems | 1 | 3 | 1 | 0 | Sajith clarifies an earlier point about email usage in response to an audience question about software boundary limits. Host engagement is minimal and friendly. |
Statements from this episode (11)
Wickramasekara: Advanced drug development lacks modern software and data infrastructure
“You would think that such deliberate advanced science would have a large amount of software and advanced data behind it as well, but that's actually not the case.”
Wickramasekara: Life science research still runs on paper, email, and Excel
“This is an industry that runs on paper, email, and Excel, and it's something that touches everyone.”
Wickramasekara: Antibody drug discovery begins with tens of thousands of candidates
“Creating something like Avastin actually involves starting with tens of thousands of candidate antibodies in the beginning.”
Wickramasekara: Curing cancer with Excel is worse than dev without version control
“They're literally trying to cure cancer using Excel. This is the equivalent of one of the companies you work at building software without version control. It's honestly probably a little worse, actually.”
Wickramasekara: Antibody drug discovery has no fixed deterministic formula
“For most antibody research. The discovery process itself is a work in process. There's no formula for spitting out a drug by going through some set of steps that's going to work.”
Wickramasekara: Scientific research can largely be broken down into processes
“Science can sometimes seem like an art, and it is to some degree, but a lot of it can be broken down into a process.”
Wickramasekara: Applying standard data practices to life sciences requires little domain expertise
“Using quite standard data practices we were able to make a big dent in a really high impact field that touches everyone and it doesn't require a ton of domain expertise.”
Wickramasekara: Most Benchling employees have no background in life science
“Most of our team actually has no background in the live science at all.”
Wickramasekara: Benchling adoption spread bottom-up from grad school to pharma giants
“It started with the younger folks. It started with folks in grad school who are going to adopt a tool out of their own volition just because it makes their lives better, and you go to the small biotechs, medium biotechs, and eventually the large companies, the…”
Wickramasekara: Clunky enterprise systems force pharma scientists to email sensitive IP
“A lot of these companies, they do have systems that exist, but they're quite clunky and not integrated. So the scientists resort to using email, and this is whatever email systems they have set up. Sometimes they're personal gmails as well.”
Wickramasekara: Expiring patents and cost pressures force pharma to adopt cloud
“The pharma industry's typically been wildly profitable, and it still is, but it's under cost pressure for the first time just because of patents expiring and that sort of thing, and therefore they're, as a result of economics, becoming more amenable to cloud s…”